Baillie Gifford & Co. Has $936.74 Million Stock Position in BioNTech SE (NASDAQ:BNTX)

Baillie Gifford & Co. reduced its holdings in BioNTech SE (NASDAQ:BNTX - Free Report) by 1.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 8,220,581 shares of the company's stock after selling 87,490 shares during the quarter. Baillie Gifford & Co. owned about 3.43% of BioNTech worth $936,735,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. FMR LLC raised its position in shares of BioNTech by 797.8% during the third quarter. FMR LLC now owns 6,299,929 shares of the company's stock valued at $748,243,000 after buying an additional 5,598,190 shares during the last quarter. Fred Alger Management LLC acquired a new stake in shares of BioNTech during the 3rd quarter valued at about $59,485,000. Braidwell LP acquired a new stake in shares of BioNTech during the 3rd quarter valued at about $29,425,000. New York State Common Retirement Fund boosted its position in shares of BioNTech by 457.9% during the 3rd quarter. New York State Common Retirement Fund now owns 218,067 shares of the company's stock valued at $25,900,000 after acquiring an additional 178,981 shares in the last quarter. Finally, abrdn plc increased its position in shares of BioNTech by 334.4% during the 3rd quarter. abrdn plc now owns 225,992 shares of the company's stock worth $26,841,000 after purchasing an additional 173,969 shares in the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Stock Down 2.5 %

Shares of BNTX stock traded down $3.06 on Wednesday, hitting $119.69. 296,420 shares of the stock were exchanged, compared to its average volume of 715,462. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The business has a 50-day moving average of $117.32 and a 200 day moving average of $110.18. The firm has a market capitalization of $28.69 billion, a P/E ratio of -57.07 and a beta of 0.17. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on BNTX shares. JPMorgan Chase & Co. dropped their target price on shares of BioNTech from $124.00 to $122.00 and set a "neutral" rating for the company in a research report on Tuesday, November 26th. Canaccord Genuity Group lifted their price objective on BioNTech from $171.00 to $171.44 and gave the stock a "buy" rating in a research report on Wednesday, November 27th. BMO Capital Markets reiterated an "outperform" rating on shares of BioNTech in a research report on Monday, December 2nd. Berenberg Bank assumed coverage on BioNTech in a research note on Tuesday, November 19th. They issued a "buy" rating and a $130.00 target price on the stock. Finally, Evercore ISI raised BioNTech from an "in-line" rating to an "outperform" rating and increased their target price for the company from $110.00 to $125.00 in a research note on Tuesday, November 19th. Three investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, BioNTech presently has an average rating of "Moderate Buy" and a consensus target price of $142.72.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.